LENSAR Reports 10% Revenue Growth to $13.9 Million in Q2 2025, Plans Merger with Alcon

LENSAR, Inc. reported a total revenue of $13.9 million for the three months ended June 30, 2025, marking a 10% increase from $12.6 million in the same period last year. For the six months ended June 30, 2025, revenue rose by 21% to $28.1 million, compared to $23.2 million in the prior year. The growth in revenue was primarily driven by increased placements and procedure volumes of the ALLY Robotic Cataract Laser System. Despite the revenue increase, the company reported a net loss of $1.8 million for the second quarter of 2025, a significant improvement from a net loss of $9.0 million in the same quarter of 2024. For the first half of 2025, the net loss was $29.1 million, compared to $11.2 million for the same period in 2024.

The company experienced notable changes in its operational metrics, with product revenue increasing by 14% to $10.9 million in Q2 2025, while service revenue rose by 20% to $1.4 million. However, lease revenue decreased by 16% to $1.6 million, attributed to a reduction in leased LENSAR Laser Systems. The total cost of revenue for the second quarter increased by 19% to $6.9 million, driven by higher costs associated with product components due to inflation and tariffs. The company’s accumulated deficit reached $172.4 million as of June 30, 2025.

Strategically, LENSAR is in the process of merging with Alcon Research, LLC, as outlined in a merger agreement signed on March 23, 2025. The merger is expected to close in the second half of 2025, pending regulatory approvals. As part of the agreement, LENSAR received a $10 million cash deposit, which is classified as a current liability. The company has incurred approximately $4.2 million in acquisition-related costs in the second quarter of 2025, reflecting the ongoing expenses associated with the merger process.

Operationally, LENSAR's installed base of systems reached approximately 410 as of June 30, 2025. The company has been expanding its commercial organization, which included about 75 professionals in the U.S. as of the reporting date. The ALLY System has received regulatory clearance in multiple regions, including the U.S., EU, India, Taiwan, and South Korea, with ongoing efforts to secure additional certifications in other markets, including China. The company anticipates that its revenue and expenses will continue to rise as it executes its growth strategy and expands its sales and customer support teams.

Looking ahead, LENSAR expects to continue incurring losses and cash outflows in the near term as it builds its commercial infrastructure and pursues further regulatory clearances for the ALLY System. The company believes that its current cash, cash equivalents, and investments will be sufficient to support operations for at least the next twelve months. However, it may need to raise additional capital in the future to fund its operations and growth initiatives, which could involve issuing new equity or debt securities. The company remains cautious about the impact of global economic conditions, supply chain disruptions, and inflation on its business and financial performance.